Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the closure of the trading window for insiders due to the upcoming declaration of audited financial results for the fiscal year ended March 31, 2022. It references regulatory provisions related to insider trading and specifies the trading window closure period but does not contain any financial data, results, or detailed report content. The document is short (1158 characters) and serves as a notification rather than a financial report or earnings release. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance-related notices that do not fit other categories.
2022-03-31 English
Code of conduct under SEBI (PIT) Regulations
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding compliance with SEBI regulations on insider trading. It announces the adoption of a new Code of Conduct for Prevention of Insider Trading and related procedures by the Board of Directors. There is no financial data, no report attached or referenced as being published, and no mention of voting results, management changes, or other report types. The document is an official regulatory announcement related to compliance and governance but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a compliance notification under SEBI regulations without substantive financial or report content.
2022-03-30 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges about the schedule of an analyst/institutional investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a meeting schedule, not a financial report, earnings release, or detailed investor presentation. The document length is only 1302 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure, not a detailed investor presentation or report.
2022-03-29 English
Communication to shareholders as per Reg 30
Regulatory Filings
2022-03-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Indoco Remedies has received USFDA approval for Lacosamide Tablets. It is addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is a corporate announcement about a regulatory approval and product launch, not a financial report, earnings release, or management discussion. The document length is 3555 characters, which is relatively short and typical for a press release. There is no financial data, no voting results, no management changes, no legal proceedings, and no detailed financial or operational report. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2022-03-22 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges about the schedule of an Analyst / Institutional Investors Meeting. It is an informational announcement about a future event, not a financial report or detailed presentation. The document length is only 1280 characters, indicating it is brief and does not contain financial data or detailed analysis. It does not contain any financial statements, earnings data, or regulatory certifications. It is not a report itself but an announcement related to investor relations. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor meetings, but since it only announces the schedule and does not provide the presentation itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor meetings under SEBI regulations.
2022-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.